zinc therapy in neonatal jaundice
Phase 2
- Conditions
- Health Condition 1: P599- Neonatal jaundice, unspecified
- Registration Number
- CTRI/2024/03/064330
- Lead Sponsor
- Gummalla Gyandeep
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Neonates with Gestational age = 35 weeks admitted in NICU for phototherapy as per UK-NICE guideline.
Exclusion Criteria
1)Severe hyperbilirubinemia( need of escalation therapy and exchange transfusion)
2)Major congenital abnormality
3) Sick neonate (sepsis, birth asphyxia, feed intolerance, mechanical ventilation, IEM) where oral feeding contraindicated.
4)Rebound hyperbilirubinemia who require phototherapy again
5) Maternal Phenobarbital intake.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome will be measured by comparing decrease in unconjugated serum bilirubin in both zinc with 5mg and 10 mg oral group along with placebo group.Timepoint: 1 month
- Secondary Outcome Measures
Name Time Method The secondary outcomes will be measured by comparing the duration of phototherapy, hospital stay, adverse events of the zinc and zinc levels pre and post phototherapy in intervention and placebo groups.Timepoint: 1 month